Copyright ©The Author(s) 2018.
World J Clin Oncol. Jun 10, 2018; 9(3): 42-55
Published online Jun 10, 2018. doi: 10.5306/wjco.v9.i3.42
Table 1 Relative amount of modification (directly quantified or extrapolated from the expression level of writers/erasers)
RNA modificationsHigh in cancerLow in cancer
m6ALung adenocarcinoma[22], AML[23]HER2 overexpressing subtypes breast cancer[35], t(11q23)/MLL-rearranged, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1-mutated AMLs (ASB2 and RARA)[36], GBM (FOXM1)[39], breast cancer (NANOG)[40]
2’O-methylationBreast cancer [51,67], primary and metastatic prostate cancers[58], squamous cell cervical carcinoma[57]
ΨLeukemia, lymphoma, multiple myeloma[84-86]
InosineBLCA, BRCA, COAD, HNSC, LUAD, THCA[87,88], NSCLC (NEIL1[94], AZIN1[103], miR-381[94]), SCLC (AZIN1)[87], HCC (AZIN1[101], FLNB[90]), GC[91], ESCC (FLNB)[92], cervical cancer[89], CRC (RHOQ)[109], AML (PTPN6)[114]KIRP, KICH[87,88], Breast cancer (Gabra3)[118], Gastric cancer (PODXL)[91], Glioblastoma (GluR-B)[119], onco miR-21, miR-221, miR-222[128], ESCC (IGFBP7)[120], Glioma (miR-376a*)[129], Melanoma[130] (miR-455-5p)[132]
5mCCirculating tumor cells in lung cancer[137]